Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2015. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes.
Key transaction details include:
- Transaction Type: Increase in interests in Ordinary Shares via dividend re-investment.
- Dividend Date: July 9, 2015.
- Share Price: 1,365.77 pence per Share.
Material Changes
The filing reports specific increases in shareholdings for the following individuals following the dividend re-investment:
- Directors/PDMRs: Sir Andrew Witty (2,039.781 shares), Mr S A Hussain (2,087.598 shares), Dr P J T Vallance (1,178.550 shares), Ms C Thomas (972.123 shares), Ms E Walmsley (914.063 shares), Mr S Dingemans (912.401 shares), Mr D S Redfern (791.924 shares), Mr P C Thomson (332.753 shares), Mr R G Connor (231.261 shares), and Dr M M Slaoui (160.090 shares).
- Connected Persons: Mrs K Thomson (107.150 shares).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares held by each Director and PDMR post-transaction to assess alignment with company performance.
- Confirm the dividend re-investment plan terms applicable to the July 9, 2015 dividend.
- Review the full annual report (Form 20-F) for comprehensive financial metrics not included in this transaction notification.